Lifeward (LFWD)
NASDAQ:LFWD
Want to see LFWD full AI Analyst Report?
Earnings Data
Report Date
Aug 12, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.81Last Year’s EPS
-3.72Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
Balanced mix of strategic, financial and operational positives (acquisitions, stronger cash position, ReWalk growth, cost reductions and reduced cash burn) offset by meaningful near-term operational headwinds (22% revenue decline, 800 bps gross margin compression, increased GAAP loss and manufacturing/supply chain disruptions). Management expects to resolve AlterG timing issues across Q2–Q3, sees a path to profitability and holds revenue expectation similar to prior year but retains execution risk during the transition.Company Guidance
Strategic Acquisition of Oratech
Completed equity-based acquisition of Oratech, gaining a protein oral delivery platform (including ORMD-0801 oral insulin expected to start Phase II). Transaction described as capital-efficient with minimal near-term operational burden and no material increase in operating expenses.
Strengthened Balance Sheet via Financing
Closed a $10.0 million convertible note financing and acquired approximately $6.5 million of cash with the Oratech transaction, increasing unrestricted cash and cash equivalents to $11.4 million from $2.2 million at year-end 2025 (net increase of $9.2 million).
ReWalk Sales Growth
ReWalk personal exoskeleton revenue increased 11% year-over-year to $1.6 million (from $1.3 million), driven by international sales, reimbursement expansion and distribution growth (Germany up ~25% quarter-over-quarter).
Expanded Reimbursement and Distribution
Progress on reimbursement access with Medicare Advantage coverage from Aetna, Humana and UnitedHealthcare and expanded distribution domestically and internationally, positioning the neurorehabilitation portfolio for long-term growth.
Operating Expense Improvements (Non-GAAP)
Adjusted operating expenses declined 12% year-over-year to $5.9 million (from $6.8 million), driven by improved productivity in sales & marketing, lower reimbursement-related costs and reduced R&D following completion of major programs.
Stable Adjusted Operating Loss and Lower Cash Burn
Non-GAAP adjusted operating loss remained unchanged year-over-year at $4.6 million despite lower revenue, and cash used in operating activities declined 33% to $3.7 million versus Q1 2025, reflecting improved operational efficiencies and working capital management.
New Product Addition — Upper Body Exoskeleton
Acquired an upper body exoskeleton technology targeting ~4.6 million stroke survivors; development work underway toward commercialization, complementing the ReWalk platform.
LFWD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
LFWD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 15, 2026 | $6.59 | $6.70 | +1.59% |
Mar 18, 2026 | $7.56 | $6.72 | -11.11% |
Nov 14, 2025 | $6.25 | $7.17 | +14.86% |
Aug 14, 2025 | $8.60 | $7.34 | -14.64% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Lifeward (LFWD) report earnings?
Lifeward (LFWD) is schdueled to report earning on Aug 12, 2026, Before Open (Confirmed).
What is Lifeward (LFWD) earnings time?
Lifeward (LFWD) earnings time is at Aug 12, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LFWD EPS forecast?
LFWD EPS forecast for the fiscal quarter 2026 (Q2) is -0.81.